Clinical Trial Detail

NCT ID NCT02619253
Title Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Roberto Pili

ureter transitional cell carcinoma

urethra transitional cell carcinoma

renal cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma


Pembrolizumab + Vorinostat

Age Groups: adult

No variant requirements are available.